Major Declarations Stocks: Novartis AG (NYSE:NVS), The Advisory Board Company (NASDAQ:ABCO

Novartis AG (NYSE:NVS) Trend Analysis issued that the US FDA Oncologic Drugs Advisory Committee or ODAC did not advocate the investigational compound LBH589 or panobinostat, a pan-deacetylase (pan-DAC) inhibitor, for patients with previously treated multiple myeloma when used in combination with bortezomib and dexamethasone. Shares of Novartis AG (NYSE:NVS) traded at $91.76 by moving down -0.29% with price volatility of 0.77% for a week and 1.19% for a month. Its beta stands at 0.49 times.The Advisory Board Company (NASDAQ:ABCO) Trend Analysis recently released that its Q2 net earnings of $6.5M or $0.18 a share as compared with $9M or $0.24 a share previous year. Excluding items, adjusted earnings for the quarter were $0.43 per share compared with $0.31 per share a year ago. The Advisory Board Company (NASDAQ:ABCO) stock has highest price of $49.62 in last session, beginning with a price of $45.97 and reported a loss of -10.65% to the closed at $48.47 with a day range of $45.00-$49.62. The stock is going forward its 52-week low with 12.72% and moving down from its 52 week high price with -30.90%.